Results of subgroup analysis of pooled HRs for OS of patients harboring K-ras mutation with EGFR-TKI treatment
| Subgroups | No. of study | Heterogeneity | Fixed model | Random model | |||||
|---|---|---|---|---|---|---|---|---|---|
| I2 (%) | P | HR (95% CI) | P | HR (95% CI) | P | ||||
| Concomitant with EGFR mutation | |||||||||
| No | 5 | 19.5 | 0.290 | 1.79 (1.35-2.36) | 0.000 | 1.83 (1.31-2.02) | 0.000 | ||
| Yes | 2 | 73.4 | 0.052 | 1.37 (0.98-1.92) | 0.069 | 1.53 (0.75-3.12) | 0.246 | ||
| NR | 3 | 0.0 | 0.477 | 1.55 (1.09-2.21) | 0.013 | 1.55 (1.09-2.21) | 0.013 | ||
| Previous treatment | |||||||||
| CT | 7 | 12.9 | 0.331 | 1.73 (1.37-2.18) | 0.000 | 1.73 (1.34-2.23) | 0.000 | ||
| Combination | 2 | 0.0 | 0.406 | 1.84 (1.17-2.90) | 0.009 | 1.84 (1.17-2.90) | 0.009 | ||
| NR | 1 | – | – | 1.10 (0.80-1.80) | 0.645 | 1.10 (0.80-1.80) | 0.645 | ||
| Mutation detection | |||||||||
| DS | 3 | 14.2 | 0.312 | 1.58 (1.07-2.35) | 0.022 | 1.59 (1.03-2.45) | 0.037 | ||
| DCE | 2 | 0.0 | 0.643 | 1.63 (1.13-2.35) | 0.008 | 1.63 (1.13-2.35) | 0.008 | ||
| RFLP | 1 | – | – | 6.20 (1.58-24.31) | 0.009 | 6.20 (1.58-24.31) | 0.009 | ||
| ME | 1 | – | – | 2.29 (1.23-4.26) | 0.009 | 2.29 (1.23-4.26) | 0.009 | ||
| Combination | 2 | 56.5 | 0.129 | 1.38 (1.04-1.83) | 0.025 | 1.37 (0.90-2.10) | 0.146 | ||
CT, chemotherapy; DS, direct sequencing; DCE, denaturing capillary electrophoresis; ME, mutant-enrich sequencing; NR, not reported; RFLP, polymerase chain reaction-restriction fragment length polymorphism; HR, hazard ratio.